Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PGEN

Precigen Inc

Mar 21 • 12:08PM ET

1.82

Dollar change +0.02
Percentage change 1.11	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX REGN GILD ILMN INCY SRPT BLUE ARWR

| Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC FESM CNCR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.55	Insider Own	44.43%	Shs Outstand	292.87M	Perf Week	1.11%
Market Cap	535.13M	Forward P/E	68.24	EPS next Y	0.03	Insider Trans	0.00%	Shs Float	162.74M	Perf Month	-7.62%
Income	-139.56M	PEG	-	EPS next Q	-0.08	Inst Own	25.98%	Short Float	13.26%	Perf Quarter	163.68%
Sales	3.96M	P/S	135.13	EPS this Y	39.36%	Inst Trans	-8.88%	Short Ratio	10.48	Perf Half Y	74.99%
Book/sh	0.19	P/B	9.63	EPS next Y	109.36%	ROA	-101.81%	Short Interest	21.57M	Perf Year	26.38%
Cash/sh	0.10	P/C	18.69	EPS next 5Y	-	ROE	-137.46%	52W Range	0.65 - 2.17	Perf YTD	62.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.94%	ROI	-232.08%	52W High	-16.13%	Beta	1.62
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	-15.17%	Gross Margin	-101.65%	52W Low	179.43%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	1.63	EPS Y/Y TTM	-49.25%	Oper. Margin	-2406.26%	RSI (14)	55.32	Volatility	7.73% 9.76%
Employees	202	Debt/Eq	0.10	Sales Y/Y TTM	-41.38%	Profit Margin	-3521.68%	Recom	1.00	Target Price	6.33
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-9.17%	Payout	-	Rel Volume	1.28	Prev Close	1.80
Sales Surprise	-60.66%	EPS Surprise	-40.38%	Sales Q/Q	-30.89%	Earnings	Mar 19 AMC	Avg Volume	2.06M	Price	1.82
SMA20	2.33%	SMA50	14.13%	SMA200	46.08%	Trades		Volume	1,146,040	Change	1.11%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Mar-19-25 07:47PM	Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript (SeekingAlpha) +7.19%
06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
Mar-13-25 08:05AM	Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
Mar-01-25 05:27PM	Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 (Insider Monkey)
08:05AM	Loading…
Feb-25-25 08:05AM	FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
08:00AM	Loading…
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
10:07AM	Loading…
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire) -13.49%
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33% +6.06%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66% -8.04%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire) +17.39%
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire) -24.66%
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-11-23 06:45PM	Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.64%
Jan-04-23 04:05PM	Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (PR Newswire) +5.41%
Dec-27-22 08:00AM	Precigens Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy (News Direct) -9.29%
Dec-19-22 04:05PM	Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.70%
Dec-12-22 07:01PM	Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients (PR Newswire)
Nov-16-22 05:07AM	Bullish: Analysts Just Made A Noticeable Upgrade To Their Precigen, Inc. (NASDAQ:PGEN) Forecasts (Simply Wall St.) -6.15%
Nov-09-22 04:05PM	Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs (PR Newswire) -8.13% +21.09%
Nov-02-22 04:30PM	Precigen to Announce Third Quarter 2022 Financial Results on November 9th (PR Newswire)
Sep-21-22 04:30PM	Precigen Names Rutul R. Shah Chief Operating Officer (PR Newswire) -13.81%
Sep-01-22 08:05AM	Precigen to Participate in the 2022 Wells Fargo Healthcare Conference (PR Newswire)
Aug-22-22 08:05AM	Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire)
Aug-08-22 04:05PM	Precigen Reports Second Quarter and First Half 2022 Financial Results (PR Newswire) +12.68%
Aug-05-22 08:36AM	Investors in Precigen (NASDAQ:PGEN) from five years ago are still down 89%, even after 32% gain this past week (Simply Wall St.)
Aug-01-22 04:05PM	Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th (PR Newswire) +9.09%
Jul-06-22 08:09AM	Reston audience measurement company comScore names its next CEO (American City Business Journals) -9.88%
Jul-05-22 08:05AM	Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire) +14.89%
Jun-27-22 04:05PM	Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit (PR Newswire)
May-17-22 04:05PM	Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference (PR Newswire)
May-14-22 08:15AM	Need To Know: Analysts Are Much More Bullish On Precigen, Inc. (NASDAQ:PGEN) Revenues (Simply Wall St.)
May-11-22 06:29AM	Earnings Update: Precigen, Inc. (NASDAQ:PGEN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts (Simply Wall St.) -7.75%
May-09-22 04:05PM	Precigen Reports First Quarter 2022 Financial Results and Business Updates (PR Newswire) -8.00% +12.17%
May-02-22 03:00PM	Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +5.26%
Apr-04-22 08:05AM	Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire) +11.45%
Apr-03-22 03:40PM	What Type Of Shareholders Make Up Precigen, Inc.'s (NASDAQ:PGEN) Share Registry? (Simply Wall St.)
Mar-01-22 08:00AM	Precigen Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Feb-02-22 10:10AM	Further weakness as Precigen (NASDAQ:PGEN) drops 10% this week, taking five-year losses to 88% (Simply Wall St.) -10.38%
Feb-01-22 09:38PM	AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ... (GuruFocus.com)
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. (American City Business Journals)
Jan-12-22 04:30PM	Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-11-22 10:00AM	Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher (Zacks)
Jan-05-22 04:05PM	Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire) -10.47%
Dec-13-21 05:05PM	Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Dec-01-21 07:56AM	A US$64m market cap addition is just what Precigen, Inc. (NASDAQ:PGEN) insiders like to see after purchasing stock worth US$3.7m (Simply Wall St.)
Nov-24-21 08:38AM	Is the Options Market Predicting a Spike in Precigen (PGEN) Stock? (Zacks) +11.57%

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRK RANDAL J	Director	Mar 14 '25	Option Exercise	0.00	174,825	0	64,779,510	Mar 17 06:38 PM
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 09 '24	Buy	0.85	58,823	50,000	743,097	Aug 13 05:09 PM
KIRK RANDAL J	Director	Aug 09 '24	Buy	0.85	23,529,411	19,999,999	64,547,214	Aug 13 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PGEN

Precigen Inc

Upgrade your FINVIZ experience